Covid 19 Research using Clinical Trials (Home Page)
Follow upWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug792 | Sterile Normal Saline for Intravenous Use Wiki | 0.71 |
| drug183 | Centricyte 1000 Wiki | 0.71 |
| drug409 | IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki | 0.71 |
| drug173 | Canakinumab Injection 600mg Wiki | 0.71 |
| drug463 | Liberase Enzyme (Roche) Wiki | 0.71 |
| drug172 | Canakinumab Injection 300mg Wiki | 0.71 |
| drug509 | Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki | 0.71 |
| drug632 | Placebos Wiki | 0.19 |
Correlated MeSH Terms (12)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D054990 | Idiopathic Pulmonary Fibrosis NIH | 0.71 |
| D011649 | Pulmonary Alveolar Proteinosis NIH | 0.71 |
| D001927 | Brain Diseases NIH | 0.50 |
| D011658 | Pulmonary Fibrosis NIH | 0.41 |
| D017563 | Lung Diseases, Interstitial NIH | 0.35 |
| D008171 | Lung Diseases, NIH | 0.35 |
| D016638 | Critical Illness NIH | 0.18 |
| D011024 | Pneumonia, Viral NIH | 0.12 |
| D003141 | Communicable Diseases NIH | 0.08 |
| D007239 | Infection NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection
Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare. The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients. Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity. Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients. We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.
NCT04320472 COVID-19 Encephalopathy Critically Ill Other: Follow up MeSH:Brain Diseases Critical Illness
HPO:Encephalopathy
Primary Outcomes
Description: ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission
Measure: prevalence Time: at Critical/Intensive care or Neurocritical care admission
Secondary Outcomes
Description: A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]
Measure: Favorable outcome Time: 3 months
2 Characteristics and Outcome of COVID-19 Among Egyptian Patients
Primary Outcomes
Description: ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission
Measure: prevalence Time: at Critical/Intensive care or Neurocritical care admissionSecondary Outcomes
Description: A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]
Measure: Favorable outcome Time: 3 monthsThe World Health Organization (WHO) has recently declared coronavirus disease 2019 (Covid-19) a public health emergency of international concern. Egypt is one of the countries that has been infected by Covid-19. The characteristics of clinical presentation, laboratory and radiological data are not yet studied. Outcomes of covid-19 in Egypt also have not been described yet.
NCT04339322 Characteristics Diseases Outcome, Fatal Other: Follow up
Primary Outcomes
Description: Sheet recording age, sex, co-morbidity,history of contact
Measure: Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group Time: 2 monthsDescription: Sheet recording symptoms and signs
Measure: Clinical manifestations of Coronavirus Disease 2019 (COVID-19) Time: 2 monthDescription: blood picture,D-Dimer, creatinine, liver enzymes
Measure: Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort Time: 2 monthsDescription: Chest x-ray and/or Computed tomography
Measure: Radiological features of Coronavirus Disease 2019 (COVID-19) cohort Time: 2 monthSecondary Outcomes
Description: Data recording of the outcomes of treatment
Measure: outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group Time: 1 week